Condition: Haematological Malignancy · Acute Myeloid Leukemia · Non Hodgkin Lymphoma · Sponsor: CellCentric Ltd.
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
This description comes directly from the study's public registry record.
Tomasz Knurowski, PhD · 07882871299 · Tomasz.Knurowski@cellcentric.com
Karen Clegg, MD, MFPM · Karen.Clegg@cellcentric.com
Always discuss trial participation with your own doctor first.
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Community Health Network | Indianapolis, Indiana, United States | Recruiting |
| The Center for Cancer and Blood Disorders (CCBD) | Bethesda, Maryland, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Penn Medicine - Abramson Cancer Center Perelman | Philadelphia, Pennsylvania, United States | Recruiting |
| Institute Bergonie | Bordeaux, France | Completed |
| Gustave Roussy | Villejuif, France | Completed |
| Hospital Germans Trias i Pujol/ ICO Badalona | Badalona, Spain | Recruiting |
| University Hospital Vall D'Hebron | Barcelona, Spain | Completed |
| Hospital Clínic de Barcelona | Barcelona, Spain | Recruiting |
| ICO L'Hospitalet (Instituto Catalán de Oncología) | Barcelona, Spain | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04068597